Clinical Trial

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-15
Trial Details
NCT Number NCT07341191
Lead Sponsor Canadian Cancer Trials Group
Collaborators: BeOne Medicines
Conditions Mantle Cell Lymphoma
Enrollment 40 participants
Start Date 2026-08-31
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11